Date: 2012-05-15
Type of information: Services contract
Compound: orphan drugs
Company: Selexis (Switzerland) Adienne Pharma (Italy)
Therapeutic area: Rare diseases
Type agreement: services
Action mechanism:
Disease:
Details: Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, has entered into a Service Agreement with Adienne Pharma&Biotech for the rapid development of a manufacturing cell line for one of Adienne’s orphan drugs.
Financial terms:
Latest news:
